PET/CT VALUE IN DIAGNOSE OF PRIMARY TUMOR ON CERVICAL LYMP NODE METASTASIS OF UNKNOWN PRIMARY TUMOR

THÀNH LUÂN PHẠM1,, Dao Tien Manh2, Cao Van Khanh2, Pham Viet Hoat2, Vu Van Bac2
1 VIỆN UNG BƯỚU VÀ Y HỌC HẠT NHÂN, BV QUÂN Y 175
2 Institute of Oncology and Nuclear Medicine - Military Hospital 175

Main Article Content

Abstract

Purpose: We conduct this survey to evaluate the role of  PET/CT on CUP patients. Describe characteristic of primary tumor.


Subject and menthod:


Results: 59 patients with cervical lymp node metastasis of CUP had PET/CT scan,  the mean age of patients was 53.6±13.3. There were 38/59 patients (64.4%) detected primary tumor by PET/CT, however, only 32/38 patients were confirmed as malignant (by pathology).  In 5/59 patients, PET/CT was not suggest the primary tumor but then identified by orther methods. The sensitivity and specificity of  PET/CT were 86.5%, 84.3%, respectively. The location of the primary tumor in 38 patients was suggest by PET/CT, mainly in head and neck area (85.7%).


Conclusion: PET/CT is a high value diagnose method in suggest primary tumor for cervical lymp node metastasis of unknown primary tumor .

Article Details

References

1. Bộ y tế, (2020), Hướng dẫn chẩn đoán và điều trị một số bệnh lý ung bướu, Nhà xuất bản Y học, tr. 164-217, 487-495.
2. Mai Trọng Khoa và cs, (2012), “Vai trò của PET/CT trong chẩn đoán ung thư chưa rõ nguyên phát”, ULR: https:// ungthubachmaivn/dao-tao--nghien-cuu/vai-tro-cua-petct-trong-chan-doan-ung-thu-chua-ro-nguyen-phathtml, ngày truy cập 25/6/2022.
3. Ngô Văn Đàn và cs, (2020), “Nghiên cứu vai trò và đặc điểm hình ảnh của 18 FDG-PET/CT trong chẩn đoán ung thư chưa rõ nguyên phát”, Tạp chí Ung thư học Việt Nam, số 5-2020, tr. 134-139.
4. Nguyễn Thế Tân và cs, (2020), “Nhận xét kết quả bước đầu vai trò của F18 FDG PET/CT trong phát hiện vị trí tổn thương ở bệnh nhân ung thư chưa rõ nguyên phát tại Bệnh viện K”, Tạp chí Điện quang, số 34, tr. 68-74.
5. Johansen J, Buus S, Loft A, Keiding S, et al, (2008), “Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study”, Head Neck, 30 (4), pp. 471-478.
6. Keller F, Psychogios G, Linke R, Lell M, et al, (2011), “Carcinoma of unknown primary in the head and neck: comparison between positron emission tomography (PET) and PET/CT”, Head Neck, 33 (11), pp. 1569-1575. 7. Kim J H, Choi K Y, Lee S H, Lee D J, et al, (2020), “The value of CT, MRI, and PET-CT in detecting retropharyngeal lymph node metastasis of head and neck squamous cell carcinoma”, BMC Med Imaging, 20 (1), pp. 88.
8. Lee M Y, Fowler N, Adelstein D, Koyfman S, et al, (2020), “Detection and Oncologic Outcomes of Head and Neck Squamous Cell Carcinoma of Unknown Primary Origin”, Anticancer Res, 40 (8), pp. 4207-4214.
9. Maghami E, Ismaila N, Alvarez A, Chernock R, et al, (2020), “Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline”, J Clin Oncol, 38 (22), pp. 2570-2596.
10. Miller F R, Hussey D, Beeram M, Eng T, et al, (2005), “Positron emission tomography in the management of unknown primary head and neck carcinoma”, Arch Otolaryngol Head Neck Surg, 131 (7), pp. 626-629.
11. Motz K, Qualliotine J R, Rettig E, Richmon J D, et al, (2016), “Changes in Unknown Primary Squamous Cell Carcinoma of the Head and Neck at Initial Presentation in the Era of Human Papillomavirus”, JAMA Otolaryngol Head Neck Surg, 142 (3), pp. 223-228.
12. Nassenstein K, Veit-Haibach P, Stergar H, Gutzeit A, et al, (2007), “Cervical lymph node metastases of unknown origin: primary tumor detection with whole-body positron emission tomography/computed tomography”, Acta Radiol, 48 (10), pp. 1101-1108.
13. Rohren E M, Turkington T G, Coleman R E, (2004), “Clinical applications of PET in oncology”, Radiology, 231 (2), pp. 305-332.
14. Rudmik L, Lau H Y, Matthews T W, Bosch J D, et al, (2011), “Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial”, Head Neck, 33 (7), pp. 935-940.